Skip to Content
Merck
All Photos(1)

Documents

N0590200

Nicotine ditartrate

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

(−)-Nicotine hydrogen tartrate salt, (−)-1-Methyl-2-(3-pyridyl)pyrrolidine (+)-bitartrate salt

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C10H14N2 · 2C4H6O6
CAS Number:
65-31-6
Molecular Weight:
462.41
EC Number:
200-607-2
UNSPSC Code:
41116107
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

nicotine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CN1CCC[C@H]1C2=CC=CN=C2.C

InChI

1S/C10H14N2.CH4/c1-12-7-3-5-10(12)9-4-2-6-11-8-9;/h2,4,6,8,10H,3,5,7H2,1H3;1H4/t10-;/m0./s1

InChI key

RYYKFQGHMYGLEL-PPHPATTJSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Nicotine ditartrate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Prototype nicotinic acetylcholine receptor agonist; naturally occurring isomer.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

Y0001023

Nicotine for system suitability, European Pharmacopoeia (EP) Reference Standard

Y0001425

Nicotine ditartrate dihydrate, European Pharmacopoeia (EP) Reference Standard

1463304

Nicotine bitartrate dihydrate, United States Pharmacopeia (USP) Reference Standard

1327408

6-Hydroxynicotinic acid, United States Pharmacopeia (USP) Reference Standard

1463371

Nicotine Related Compound F, United States Pharmacopeia (USP) Reference Standard

1463337

Nicotine Related Compound B, United States Pharmacopeia (USP) Reference Standard

1463382

Nicotine Related Compound G, United States Pharmacopeia (USP) Reference Standard

1463326

Nicotine Related Compound A, United States Pharmacopeia (USP) Reference Standard

1463348

Nicotine Related Compound C, United States Pharmacopeia (USP) Reference Standard

1463360

Nicotine Related Compound E, United States Pharmacopeia (USP) Reference Standard

1463359

Nicotine Related Compound D, United States Pharmacopeia (USP) Reference Standard

BP822

Nicotine impurity standard, British Pharmacopoeia (BP) Reference Standard

BP821

(−)-Nicotine hydrogen tartrate salt dihydrate, British Pharmacopoeia (BP) Reference Standard

PHR2533

Nicotine Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2470

6-Hydroxynicotinic acid, Pharmaceutical Secondary Standard; Certified Reference Material

PHR3060

Nicotine Related Compound A/EP Impurity A, pharmaceutical secondary standard, certified reference material

PHR3061

Nicotine Related Compound B, pharmaceutical secondary standard, certified reference material

PHR3063

Nicotine Related Compound F, pharmaceutical secondary standard, certified reference material

PHR3064

Nicotine Related Compound G, pharmaceutical secondary standard, certified reference material

Signal Word

Danger

Hazard Statements

H301,H319,H330,H361d,H411

Hazard Classifications

Acute Tox. 2 Inhalation - Acute Tox. 3 Oral - Aquatic Chronic 2 - Eye Irrit. 2 - Repr. 2

Storage Class Code

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

WGK

WGK 2

Flash Point(F)

289.8 °F

Flash Point(C)

143.2 °C

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 3

1 of 3

(±)-Nicotine ≥99% (TLC), liquid

Sigma-Aldrich

N0267

(±)-Nicotine

(−)-Nicotine solution 1.0 mg/mL, analytical standard, for drug analysis

Supelco

N5511

(−)-Nicotine solution

(-)-Nicotine for synthesis

Sigma-Aldrich

8.20877

(-)-Nicotine

Xueliang Shang et al.
Molecular neurobiology, 54(6), 4644-4658 (2016-07-14)
The aim of this study was to examine if nicotine was able to improve cognition deficits in a mouse model of chronic mild stress. Twenty-four male C57BL/6 mice were divided into three groups: control, stress, and stress with nicotine treatment.
Gabriel Quiroz et al.
Frontiers in pharmacology, 10, 1429-1429 (2019-12-19)
Brain nicotinic acetylcholine receptors (nAChRs), a heterogeneous family of pentameric acetylcholine-gated cation channels, have been suggested as molecular targets for the treatment of alcohol abuse and dependence. Here, we examined the effect of the competitive nAChR antagonist UFR2709 on the
José-Rubén García-Montes et al.
Molecular neurobiology, 56(6), 4037-4050 (2018-09-28)
L-DOPA is the main pharmacological therapy for Parkinson's disease. However, long-term exposure to L-DOPA induces involuntary movements termed dyskinesia. Clinical trials show that dyskinesia is attenuated by metabotropic glutamate receptor type 5 (mGluR5) antagonists. Further, the onset of dyskinesia is
Marianne Husson et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 40(17), 3465-3477 (2020-03-19)
Nicotine addiction, through smoking, is the principal cause of preventable mortality worldwide. Human genome-wide association studies have linked polymorphisms in the CHRNA5-CHRNA3-CHRNB4 gene cluster, coding for the α5, α3, and β4 nicotinic acetylcholine receptor (nAChR) subunits, to nicotine addiction. β4*nAChRs
Filip S Polli et al.
Neuropharmacology, 137, 71-85 (2018-05-12)
Despite dissemination of information regarding the harm on fetal development of smoking while pregnant, the number of pregnancies associated with nicotine exposure appears to have stagnated. Presence of nicotine during neural formulation is associated with a higher susceptibility of drug
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service